Form 4: Terns Pharmaceuticals Director Acquires Stock Options in Lieu of Cash Retainer

Terns Pharmaceuticals director Jeffrey B Kindler acquired 10,657 stock options in lieu of a $40,000 cash retainer.

Summary

• Jeffrey B Kindler, a director at Terns Pharmaceuticals, acquired 10,657 stock options on February 1, 2025.
• These options were granted in lieu of a $40,000 cash retainer fee for 2025.
• The options have an exercise price of $4.46 per share and will vest monthly over a year, starting January 1, 2025, becoming fully vested by January 1, 2026.
• The options expire on January 31, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally positive as it aligns director interests with shareholders. There are no negative implications.

Positives

• The director's decision to take stock options instead of cash may indicate confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Industry Context

This is a standard practice for compensating board members, aligning their interests with shareholders through equity-based compensation.

Comparison to Industry Standards

• Many biotech companies use stock options as part of director compensation packages.
• The vesting schedule of 12 months is a common practice to ensure long-term commitment.
• The exercise price of $4.46 is specific to Terns Pharmaceuticals and would need to be compared to other similar companies to assess its relative value.

Stakeholder Impact

• Shareholders may view this as a positive sign of director commitment.
• The director's compensation is now tied to the company's stock performance.

Key Dates

Keywords

stock options, director compensation, insider trading, Terns Pharmaceuticals, equity, vesting